A Two-Single-Nucleotide Polymorphism Haplotype in Promoter Region of CYP11B2 Gene Affects Plasma Aldosterone Concentration: A Matched Case-Control Study

Details
Parent Category: Year 2020, Volume 12
Category: Volume 12, Issue 4, October-December 2020
Hits: 1279
Abstract
Background: Aldosterone synthesized by aldosterone synthase plays an imperative role in Renin-Angiotensin-Aldosterone System (RAAS). Evidence suggested that aldosterone synthase gene (CYP11B2) variants are associated with the Essential Hypertension (EH). 
Objective: The aim of the present study was to determine the association of -344T/C and -470C/T Single Nucleotide Polymorphisms (SNPs) of the CYP11B2 and their resulted haplotypes with EH and Plasma Aldosterone Concentration (PAC) in southern population of Iran. 
Methods: In this matched case-control study performed on southern Iranians, 45 patients with EH as well as 43 age- and sex-matched normotensive subjects were registered from September 2017 to September 2018. All the individuals were screened by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) for CYP11B2 related genotypes and haplotypes; PAC was also measured. The gathered data were then analyzed using SPSS16 software by the independent-samples t-test and chi-square test.  Deviations of genotype frequencies from Hardy-Weinberg Equilibrium (HWE) and differences between allele frequencies and genotype distributions were calculated by Chi-square test. For performing haplotype analysis and pairwise Linkage Disequilibrium (LD) among the genotypes, SNP analyzer version 2 software and SHEsis online server were utilized. The association of PAC with each one of the polymorphisms and haplotypes was also analyzed by multinomial logistic regression.
Results: There was no association among -344T/C and -470C/T variants and the susceptibility to EH (p=0.53, OR=0.72 and p=0.27, OR=1.69, respectively). Haplotype analysis has also found no association with the disease (CT: p=0.43, OR=1.26; TC: p=0.68, OR=0.88; and TT: p=0.56, OR=0.77). On the other hand, although -344T/C and -470C/T polymorphisms showed no association with PAC (p=0.97, OR=1.00 and p=0.70, OR=0.98, respectively), a significant relationship was found between the H3 haplotype (TT) and PAC (p=0.039, OR=1.29). 
Conclusion: Our findings indicated that TT, as the two-single-nucleotide polymorphism haplotype in promoter region of CYP11B2 gene, is associated with plasma aldosterone concentration in the southern population of Iran. So, these people are likely to be at higher risk of cardiovascular or kidney disease compared to the other investigated haplotypes.
 
Keywords: CYP11B2, Genetic polymorphism, Haplotype, PAC

 

» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/7767

The  most recent editorial (June 2021)

Ethics of Publishing Case Reports: Do We Need Ethics Approval and Patient Consent?

An editorial by Dr. Mehrdad Jalalian

Read more.

The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.

 

To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here

 

Our previous editorial (June 2020)

Lessons from COVID-19 pandemic and the Morocco’s success story.

An editorial by Dr. Benksim Abdelhafid (Morocco)

Read more.

 

The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:

 

TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:

Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: